StockNews.AI

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

StockNews.AI • 2 hours

NVDA
High Materiality8/10

Information

SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” o...

Original source

AI Summary

Shareholders approved key resolutions at the Special Meeting on January 15. Company will transition from Canada to Nevada for better regulatory advantages. New 2026 Incentive Award Plan is set to enhance employee retention and motivation. Pelareorep shows promising results in cancer studies boosting future commercialization potential.

Sentiment Rationale

The successful resolutions reflect strong shareholder support, potentially enhancing investor confidence. Historical trends indicate that positive corporate governance actions can lead to stock price increases.

Trading Thesis

The immediate expectation of operational advantages from the resolutions may influence short-term trading behavior, as companies often see a price journey upon announcements of such resolutions.

Market-Moving

  • Shareholders approved key resolutions at the Special Meeting on January 15.
  • Company will transition from Canada to Nevada for better regulatory advantages.
  • New 2026 Incentive Award Plan is set to enhance employee retention and motivation.

Key Facts

  • Shareholders approved key resolutions at the Special Meeting on January 15.
  • Company will transition from Canada to Nevada for better regulatory advantages.
  • New 2026 Incentive Award Plan is set to enhance employee retention and motivation.
  • Pelareorep shows promising results in cancer studies boosting future commercialization potential.

Companies Mentioned

  • NVDA (NVDA)

Corporate Developments

The resolutions signify strategic decisions that streamline operations, likely leading to improved investor sentiment and potential operational efficiencies.

Oncolytics Biotech® Reports Positive Shareholder Meeting Results

On January 15, 2026, Oncolytics Biotech® Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company known for its development of pelareorep, announced the successful outcomes of its Special Meeting of Shareholders. All proposed resolutions aimed at improving the Company's operational and regulatory frameworks were approved by shareholders.

Key Voting Results from the Special Meeting

The Special Meeting, held in San Diego, saw significant support for all items outlined in the management circular dated December 9, 2025. The detailed voting results are as follows:

  • Continuance Resolution: 14,994,075 votes (85.21%) in favor, 2,602,405 votes (14.79%) against
  • Domestication Resolution: 15,304,574 votes (86.98%) in favor, 2,291,905 votes (13.02%) against
  • 2026 Incentive Award Plan Resolution: 13,508,657 votes (76.77%) in favor, 4,087,822 votes (23.23%) against

Implications of the Approved Resolutions

Approval of the Continuance Resolution allows Oncolytics to transition from Alberta, Canada, to British Columbia. Subsequently, the Domestication Resolution enables the move from British Columbia to Nevada, USA. These steps are designed to enhance corporate governance and agility.

The third resolution, pertaining to the 2026 Incentive Award Plan, will come into effect following the successful implementation of the Continuance and Domestication. The Company anticipates finalizing these changes by the end of Q1 2026.

More About Oncolytics Biotech Inc.

Oncolytics Biotech is at the forefront of developing pelareorep, an innovative double-stranded RNA immunotherapeutic agent. Pelareorep is currently under investigation for its efficacy in various cancers, including pancreatic and breast cancers. The agent has shown promising results in clinical trials, with faster routes of development due to Fast Track designation from the FDA.

Oncolytics is actively exploring strategic partnerships to amplify the development and commercial potential of pelareorep, with a focus on maximizing patient impact through innovative immunotherapy solutions.

For further details on the Special Meeting and additional information about Oncolytics Biotech, please visit www.oncolyticsbiotech.com or follow the Company on LinkedIn and X @oncolytics.

Forward-Looking Statements

This announcement contains forward-looking statements as defined under the U.S. Securities Exchange Act of 1934. These include indications regarding the expected timelines for the Continuance, Domestication, and the 2026 Incentive Award Plan. While Oncolytics believes these statements are reasonable, there are inherent risks that could lead to actual results diverging from current expectations.

For ongoing updates and detailed information, stakeholders are encouraged to review Oncolytics’ public filings with securities regulators in the U.S. and Canada.

Contact Information

For inquiries, contact:

Related News